Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company’s web site at http://www.gentium.com.
- 18 years ago
QualityStocks
Gentium S.p.A. (NASDAQ: GENT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…